[go: up one dir, main page]

DE69833264D1 - Verfahren und zusammensetzungen für die krebstherapie unter verwendung von interferon-beta codierenden genen - Google Patents

Verfahren und zusammensetzungen für die krebstherapie unter verwendung von interferon-beta codierenden genen

Info

Publication number
DE69833264D1
DE69833264D1 DE69833264T DE69833264T DE69833264D1 DE 69833264 D1 DE69833264 D1 DE 69833264D1 DE 69833264 T DE69833264 T DE 69833264T DE 69833264 T DE69833264 T DE 69833264T DE 69833264 D1 DE69833264 D1 DE 69833264D1
Authority
DE
Germany
Prior art keywords
interferon
compositions
cancer therapy
coding genes
expression system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833264T
Other languages
English (en)
Other versions
DE69833264T2 (de
Inventor
G Barsoum
Xiao-Qiang Qin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DE69833264D1 publication Critical patent/DE69833264D1/de
Publication of DE69833264T2 publication Critical patent/DE69833264T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69833264T 1997-08-29 1998-08-25 Verfahren und zusammensetzungen für die krebstherapie unter verwendung von interferon-beta codierenden genen Expired - Lifetime DE69833264T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
US57254P 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (2)

Publication Number Publication Date
DE69833264D1 true DE69833264D1 (de) 2006-04-06
DE69833264T2 DE69833264T2 (de) 2006-09-28

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833264T Expired - Lifetime DE69833264T2 (de) 1997-08-29 1998-08-25 Verfahren und zusammensetzungen für die krebstherapie unter verwendung von interferon-beta codierenden genen

Country Status (25)

Country Link
EP (1) EP1007717B8 (de)
JP (3) JP4124565B2 (de)
KR (1) KR100699285B1 (de)
CN (1) CN100342019C (de)
AT (1) ATE316145T1 (de)
AU (1) AU740428B2 (de)
BR (1) BR9812138A (de)
CA (1) CA2300480C (de)
CY (1) CY1105029T1 (de)
CZ (2) CZ297314B6 (de)
DE (1) DE69833264T2 (de)
DK (1) DK1007717T3 (de)
EA (1) EA003256B1 (de)
EE (1) EE04873B1 (de)
ES (1) ES2257817T3 (de)
HK (1) HK1029599A1 (de)
HU (1) HU224422B1 (de)
IL (2) IL134593A0 (de)
IS (1) IS2318B (de)
NO (1) NO20000990L (de)
NZ (1) NZ503401A (de)
PT (1) PT1007717E (de)
SK (1) SK286821B6 (de)
TR (1) TR200000532T2 (de)
WO (1) WO1999010516A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502585A (ja) * 2001-01-22 2005-01-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド 治療的核酸の送達を増強するための方法
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (de) * 2006-03-14 2007-09-19 Université de Liège Selbst-inaktivierender rekombinanter lentiviraler Vektor zur Inhibierung von HIV
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
US20190125804A1 (en) * 2016-06-15 2019-05-02 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
KR20220025757A (ko) * 2019-06-01 2022-03-03 시벡 바이오테크놀로지스, 엘엘씨 진핵 세포에 유전자 편집 시스템을 전달하기 위한 박테리아 플랫폼

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
CA2156132A1 (en) * 1994-08-16 1996-02-17 Abraham Bout Recombinant vectors derived from adenovirus for use in gene therapy
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
WO1999010516A2 (en) 1999-03-04
AU9205198A (en) 1999-03-16
JP3953458B2 (ja) 2007-08-08
SK2482000A3 (en) 2000-08-14
CZ297314B6 (cs) 2006-11-15
EP1007717B1 (de) 2006-01-18
EP1007717A2 (de) 2000-06-14
JP4124565B2 (ja) 2008-07-23
CZ2000733A3 (cs) 2000-06-14
IL134593A0 (en) 2001-04-30
HUP0002913A2 (hu) 2000-12-28
JP4219335B2 (ja) 2009-02-04
EP1007717B8 (de) 2006-05-03
DK1007717T3 (da) 2006-05-29
EA200000270A1 (ru) 2000-10-30
CA2300480C (en) 2010-01-05
CA2300480A1 (en) 1999-03-04
CN1271391A (zh) 2000-10-25
EE04873B1 (et) 2007-08-15
CZ299095B6 (cs) 2008-04-23
CY1105029T1 (el) 2010-03-03
EA003256B1 (ru) 2003-02-27
PT1007717E (pt) 2006-06-30
CN100342019C (zh) 2007-10-10
NO20000990D0 (no) 2000-02-28
HU224422B1 (hu) 2005-08-29
IL134593A (en) 2007-06-17
IS2318B (is) 2007-11-15
JP2005225888A (ja) 2005-08-25
AU740428B2 (en) 2001-11-01
BR9812138A (pt) 2000-07-18
JP2004155786A (ja) 2004-06-03
EE200000102A (et) 2000-12-15
TR200000532T2 (tr) 2000-11-21
WO1999010516A3 (en) 1999-05-06
DE69833264T2 (de) 2006-09-28
ATE316145T1 (de) 2006-02-15
KR100699285B1 (ko) 2007-03-26
JP2001514010A (ja) 2001-09-11
IS5374A (is) 2000-02-11
KR20010023511A (ko) 2001-03-26
HUP0002913A3 (en) 2003-08-28
ES2257817T3 (es) 2006-08-01
NZ503401A (en) 2003-01-31
SK286821B6 (sk) 2009-06-05
NO20000990L (no) 2000-05-02
HK1029599A1 (en) 2001-04-06

Similar Documents

Publication Publication Date Title
CY1105029T1 (el) Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα
ATE192500T1 (de) Rekombinante viren vektoren zur expression in muskelzellen
DE69426328D1 (de) Verwendung von mesothelialen zellen in der gentherapie
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
ATE377075T1 (de) Rekombinante glycoproteine, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und ihre verwendung
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
ATE157012T1 (de) Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
UA84387C2 (ru) Человеческий цитокин как лиганд зальфа рецептора и его применение
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
ATE290789T1 (de) Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration
FI942442A0 (fi) Proteiinien tuotto 7B2-proteiinia käyttäen
NO991839L (no) FremgangsmÕter og preparater for utlevering og ekspresjon av interferon-<alfa>-nukleinsyrer
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
ATE265526T1 (de) Genetisch veränderte fibroblasten und ihre verwendung
DE60035504D1 (de) Verfahren für die verabreichung von heilmitteln mittels einer dextrinlösung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition